| Product revenue | 23.67M |
| Cost of product revenue | 18.95M |
| Gross margin | 4.72M |
| Research and development | 2.58M |
| Selling, general and administrative | 8.02M |
| Restructuring charge | 581.6K |
| Total operating expenses from continuing operations | 11.18M |
| Operating loss from continuing operations | -6.46M |
| Change in fair value of subordinated convertible notes and warrant liabilities | |
| Other (loss) income, net | -170.32K |
| Interest income | 11.01K |
| Interest expense | -605.59K |
| Loss from continuing operations before discontinued operations | |
| Gain on sale of discontinued operations, net | |
| Income from discontinued operations, net | |
| Net loss | |
| Deemed dividend and accretion on Series C preferred stock | |
| Dividend on Series C preferred stock | |
| Net loss attributable to common stockholders | |
| From loss from continuing operations before discontinued operations attributable to common stockholders (in dollars per share) | |
| From income from discontinued operations (in dollars per share) | |
| From gain on sale of discontinued operations (in dollars per share) | |
| Net loss attributable to common stockholders per weighted average share, basic and diluted (in dollars per share) | -0.37 |
| Weighted average number of common shares, basic (in shares) | |
| Weighted average number of common shares, diluted (in shares) | |